BB Biotech's 2025 Annual Report Highlights Strong Financial Gains

BB Biotech has released its 2025 annual report, showcasing a robust performance and significant portfolio value realization. The company achieved total returns of +34.2% in CHF, +37.0% in EUR, and +53.7% in USD, surpassing the Nasdaq Biotechnology Index in USD. The net asset value (NAV) grew by +26.5% in CHF, +27.8% in EUR, and +44.8% in USD.

BB Biotech reported a net profit of CHF 578 million, a substantial increase from the previous year's CHF 76 million. The company proposes a dividend of CHF 2.25 per share, demonstrating a commitment to shareholder returns. During 2025, five portfolio companies were acquired, underscoring the focus on clinically mature and differentiated assets.

Throughout the year, BB Biotech refined its investment process and valuation framework, enhancing risk assessment and capital allocation strategies. They initiated new positions and increased others, emphasizing assets with clear development paths. The share buyback program continues, allowing repurchase of up to 10% of shares over three years.